Myofibroblasts are the principal effector cells driving fibrosis, and their accumulation in
tissues is a fundamental feature of fibrosis. Essential pathways have been identified as …

The hormone relaxin-2 has emerged as a promising player in regulating the physiology of
the cardiovascular system. Through binding to the relaxin family peptide receptor 1 (RXFP1) …

Relaxin H2 is a clinically relevant peptide agonist for relaxin family peptide receptor 1
(RXFP1), but a combination of this hormone's short plasma half-life and the need for …

Increasing knowledge of the processes leading to heart failure (HF) has allowed significant
developments in therapies for HF over the past few decades. Despite the evolution of HF …

Background The therapeutic potential of relaxin for heart failure and renal disease in clinical
trials is hampered by the short half‐life of serelaxin. Optimization of fatty acid‐acetylated …

The peptide hormone relaxin plays a critical role in tissue remodeling in a variety of tissues
through activation of its cognate receptor, RXFP1. Relaxin's ability to modify extracellular …

Abstract Relaxin-2 (RLX), a critical hormone in pregnancy, has been investigated as a
therapy for heart failure. In most studies, the peptide was delivered continuously …

Heart failure (HF) is a complex, progressive disorder that is associated with substantial
morbidity and mortality on a global scale. Relaxin‐2 is a naturally occurring hormone that …

Human relaxin-2 (H2 relaxin) is a peptide hormone of about 6 kDa, first identified as a
reproductive hormone involved in vasoregulation during pregnancy. It has recently attracted …

Abstract Background and Hypothesis Volenrelaxin, is a half-life-extended recombinant
human relaxin protein developed for improving kidney perfusion and cardiorenal function …